Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OSTX OS Therapies	$1.84 +1.7%	$1.76	$1.12 ▼ $7.00	$51.70M	N/A	460,076 shs	254,659 shs
SCLX Scilex	$6.05 +14.2%	$4.99	$3.60 ▼ $78.05	$42.06M	1.13	67,948 shs	181,514 shs
TLPH Talphera	$0.47 +6.4%	$0.50	$0.43 ▼ $1.19	$9.60M	-0.11	70,820 shs	164,215 shs
XFOR X4 Pharmaceuticals	$1.83 -8.5%	$3.50	$1.81 ▼ $26.96	$10.59M	0.67	127,226 shs	965,174 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OSTX OS Therapies	0.00%	+3.37%	+20.26%	+19.48%	+183,999,900.00%
SCLX Scilex	0.00%	+23.22%	+17.93%	-30.44%	-91.04%
TLPH Talphera	0.00%	+2.74%	-2.52%	-5.45%	-47.42%
XFOR X4 Pharmaceuticals	0.00%	-31.46%	-45.70%	-74.20%	-89.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OSTX OS Therapies	2.358 of 5 stars	3.7	0.0	0.0	1.8	1.7	0.6
SCLX Scilex	2.2937 of 5 stars	3.3	2.0	0.0	2.7	1.7	0.6
TLPH Talphera	2.5435 of 5 stars	3.8	3.0	0.0	2.7	0.0	0.6
XFOR X4 Pharmaceuticals	4.7742 of 5 stars	3.5	2.0	4.6	2.2	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OSTX OS Therapies	3.40	Buy	$18.00	878.26% Upside
SCLX Scilex	2.50	Moderate Buy	$455.00	7,420.66% Upside
TLPH Talphera	3.50	Strong Buy	$5.00	968.38% Upside
XFOR X4 Pharmaceuticals	3.00	Buy	$72.33	3,852.64% Upside

Current Analyst Ratings Breakdown

Latest TLPH, XFOR, SCLX, and OSTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/2/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $7.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/11/2025	SCLX Scilex	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/11/2025	SCLX Scilex	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/2/2025	OSTX OS Therapies	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
4/2/2025	SCLX Scilex	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$770.00 ➝ $630.00
4/1/2025	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	$56.59M	0.74	N/A	N/A	($27.68) per share	-0.22
TLPH Talphera	$650K	14.76	N/A	N/A	$0.47 per share	1.00
XFOR X4 Pharmaceuticals	$2.56M	4.14	N/A	N/A	$3.90 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
SCLX Scilex	-$72.81M	-$29.02	N/A	N/A	N/A	-146.93%	N/A	-82.65%	8/12/2025 (Estimated)
TLPH Talphera	-$13M	-$0.45	N/A	N/A	N/A	N/A	-130.28%	-59.25%	8/13/2025 (Estimated)
XFOR X4 Pharmaceuticals	-$37.45M	$2.14	0.85	N/A	N/A	46.54%	-181.56%	-54.36%	8/6/2025 (Estimated)

Latest TLPH, XFOR, SCLX, and OSTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/1/2025	Q1 2025	XFOR X4 Pharmaceuticals	-$4.13	$0.04	+$4.17	$0.04	$7.03 million	$28.81 million
3/31/2025	Q4 2024	TLPH Talphera	-$0.21	-$0.07	+$0.14	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OSTX OS Therapies	N/A	0.76	0.76
SCLX Scilex	N/A	0.10	0.09
TLPH Talphera	N/A	3.11	3.11
XFOR X4 Pharmaceuticals	3.30	3.70	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OSTX OS Therapies	N/A
SCLX Scilex	69.67%
TLPH Talphera	37.67%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
OSTX OS Therapies	13.80%
SCLX Scilex	7.94%
TLPH Talphera	3.20%
XFOR X4 Pharmaceuticals	2.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A
SCLX Scilex	80	6.95 million	6.40 million	Optionable
TLPH Talphera	19	20.50 million	19.85 million	Optionable
XFOR X4 Pharmaceuticals	80	5.79 million	5.67 million	Optionable

TLPH, XFOR, SCLX, and OSTX Headlines

Recent News About These Companies

XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

June 16, 2025 | globenewswire.com

X4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia Drug

June 10, 2025 | marketwatch.com

X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia

June 10, 2025 | msn.com

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

June 10, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

X4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA Congress

May 16, 2025 | nasdaq.com

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025 | globenewswire.com

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...

May 2, 2025 | finance.yahoo.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript

May 2, 2025 | insidermonkey.com

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025 | seekingalpha.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | finance.yahoo.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | globenewswire.com

X4 Pharmaceuticals Q1 2025 Earnings Preview

April 30, 2025 | msn.com

X4 Pharmaceuticals Analyst Ratings

April 30, 2025 | benzinga.com

Earnings Preview For X4 Pharmaceuticals

April 30, 2025 | benzinga.com

Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

April 30, 2025 | insidermonkey.com

X4 Pharmaceuticals To Implement 1-for-30 Reverse Stock Split On April 28

April 26, 2025 | nasdaq.com

X4 Pharmaceuticals trading halted, news pending

April 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals announces 1-for-30 reverse stock split

April 25, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH, XFOR, SCLX, and OSTX Company Descriptions

OS Therapies NYSE:OSTX

$1.84 +0.03 (+1.66%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.89 +0.05 (+2.72%)

As of 06/27/2025 07:57 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Scilex NASDAQ:SCLX

$6.05 +0.75 (+14.15%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.06 +0.00 (+0.08%)

As of 06/27/2025 07:57 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Talphera NASDAQ:TLPH

$0.47 +0.03 (+6.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.47 +0.00 (+0.64%)

As of 06/27/2025 04:26 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

X4 Pharmaceuticals NASDAQ:XFOR

$1.83 -0.17 (-8.50%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.88 +0.05 (+3.01%)

As of 06/27/2025 07:57 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time